Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Limited has informed the exchange regarding submission of Machine Readable copy of Financial results for the quarter ended June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 24 Jul 2026, 02:12 PM IST · BSE ID: a7cc9fa5-4e3e-42ec-9beb-1815c1592e35
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board has approved its first-quarter financial results, reporting a net profit of Rs. 16.31 Crores.
🤖 AI Summary
- Solara Active Pharma Sciences Board approved Q1 FY27 consolidated unaudited financial results on July 23, 2026.
- Consolidated net profit for the quarter ended June 30, 2026, was Rs. 16.31 Crores.
- Consolidated revenue from operations for Q1 FY27 stood at Rs. 381.60 Crores.
- Deloitte Haskins & Sells, Statutory Auditor, provided a Limited Review Report for the unaudited financial results.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
381.60 Rs. In Crores
19.57
Profit/(loss) for the period (Q1 FY27)
16.31 Rs. In Crores
55.04
Basic Earnings per equity share (Q1 FY27)
3.52 Rs.
43.09
Paid-up equity share capital (Q1 FY27)
48.06 Rs. In Crores
8.40
🏢 How This Affects the Company
Consolidated revenue from operations for the quarter ended June 30, 2026, was Rs. 381.60 Crores, compared to Rs. 319.15 Crores in the corresponding prior year quarter, indicating business growth.
The consolidated net profit of Rs. 16.31 Crores for Q1 FY27 shows positive earnings for the period, impacting overall financial performance.
The Statutory Auditor's Limited Review Report did not identify any material misstatement in the financial results, indicating standard financial reporting practices.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing.
👤
Who Is Affected
All equity shareholders are affected by the reported consolidated net profit of Rs. 16.31 Crores and diluted EPS of Rs. 3.52 for the quarter ended June 30, 2026.
🔍
Management Signal
Management is providing timely disclosure of quarterly financial results and ensuring review by statutory auditors, indicating adherence to regulatory requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check for sustained revenue and profit growth.
Any updates on tax expense strategy in subsequent quarters.
Management commentary on performance of unreviewed subsidiaries.
LOW RISK
The financial results are audited by Deloitte Haskins & Sells with an unmodified opinion for the main entity.
💡 Investor Takeaway
Solara Active Pharma Sciences reported a consolidated net profit of Rs. 16.31 Crores for the quarter ended June 30, 2026, a 55.04% increase from Rs. 10.52 Crores in Q1 FY26. Consolidated revenue from operations grew to Rs. 381.60 Crores, up 19.57% YoY.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated profit for the quarter ended June 30, 2026, was Rs. 16.31 Crores, an increase from Rs. 10.52 Crores YoY.
- Consolidated revenue from operations for Q1 FY27 was Rs. 381.60 Crores, rising from Rs. 319.15 Crores YoY.
⚠️ Concerns
- Total tax expense was reported as Nil for the quarter ended June 30, 2026.
- The consolidated unaudited financial results include interim financial information of 2 subsidiaries not reviewed by their auditors.
📅 Company Track Record
Solara Active Pharma Sciences reported Q4 FY26 base business revenue up 36% YoY, but the Ibuprofen business reported a negative INR 179mn EBITDA. The Board approved FY26 audited results and Q4 unaudited results on May 15, 2026. Prior filings from July 23, 2026, indicated the Board had already approved Q1 FY27 unaudited results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Solara Active Pharma Sciences' consolidated net profit for Q1 FY27?
Solara Active Pharma Sciences reported a consolidated net profit of Rs. 16.31 Crores for the quarter ended June 30, 2026.
What was Solara Active Pharma Sciences' consolidated revenue from operations for Q1 FY27?
The consolidated revenue from operations for Solara Active Pharma Sciences for the quarter ended June 30, 2026, was Rs. 381.60 Crores.
What was the Basic Earnings Per Share (EPS) for Solara Active Pharma Sciences in Q1 FY27?
The Basic Earnings Per Share for Solara Active Pharma Sciences for the quarter ended June 30, 2026, was Rs. 3.52.
Who is the Statutory Auditor for Solara Active Pharma Sciences' Q1 FY27 results?
Deloitte Haskins & Sells, Chartered Accountants, are the Statutory Auditors who issued the Limited Review Report for Solara Active Pharma Sciences' Q1 FY27 financial results.
Questions based on this BSE filing only. For information purposes.